Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Cibinqo Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy N/A

    Cibinqo (abrocitinib) Prior Authorization for Atopic Dermatitis

    Customize your policy alerts

    Sign up for all Colorado Rocky Mountain Health Plans policy alerts

    Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Cibinqo tablets used to treat moderate-to-severe atopic dermatitis in adults and patients age 12 years and older. It defines initial authorization, continuation, documentation, prescriber, treatment-history, and combination-therapy requirements.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyCibinqo (abrocitinib) Prior Authorization for Atopic Dermatitis
    Policy CodePolicy N/A
    Change TypeMinor revision
    Effective DateOct 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of a three-month systemic atopic-dermatitis treatment trial and physician attestation of inadequate control for standard initial authorization.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was reviewed with no change to the critical coverage criteria.

    The background was updated to reflect the indication for patients 12 years of age and older.

    The topical-therapy step requirement was updated to include generic pimecrolimus and tacrolimus.

    Topical corticosteroid potency categories were clarified without changing clinical intent or coverage criteria.

    Ebglyss was added as an example of a systemic drug product and Nemluvio was added as a try-and-fail option.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 moInitial authorization duration
    12 moReauthorization duration
    3 moSystemic treatment trial
    2 classesTopical-therapy classes required
    12+Minimum age
    3Accepted prescriber specialties

    Coverage Criteria

    Initial authorization

    Covered for initial authorization when all applicable requirements are met.

    • Diagnosis

      • The patient has moderate-to-severe chronic atopic dermatitis.
    • Qualifying treatment-history pathway

      • New-to-therapy pathway

        • Topical therapy history: The patient has a history of failure, contraindication, or intolerance to two of the following therapeutic classes: a medium-, high-, or very-high-potency topical corticosteroid; a topical calcineurin inhibitor; or Eucrisa (crisaborole).2 classes

          Document the drug, date of trial, and/or contraindication. Eucrisa requires prior authorization.

        • Systemic or needle-phobia pathway

          • Systemic trial with inadequate control: Medical records document a three-month trial of a systemic drug product for atopic dermatitis, and the physician attests that the patient was not adequately controlled with the documented systemic drug product.3 months

            Claims history may supplement documentation of medication use, dose, and duration. For Connecticut, Kentucky, and Mississippi business, a 30-day trial is required.

          • Systemic treatment inadvisable: The physician attests that treatment with all of Adbry, Dupixent, Ebglyss, and Nemluvio is inadvisable and documents each drug and contraindication rationale.
          • Qualifying needle phobia: The patient has documented needle phobia to the degree that the patient has previously refused any injectable therapy or medical procedure.

            DSM-V-TR 300.29 is referenced for specific-phobia diagnostic criteria.

      • Established Cibinqo user: The patient is currently receiving Cibinqo, documented through claims history or medical records with the date and duration of therapy, and did not establish current use through a free manufacturer-supplied sample or Pfizer dermatology patient-access assistance.

        Patients established through manufacturer assistance must meet the new-to-therapy criteria.

    • Safety and prescriber requirements

      • The patient is not receiving Cibinqo in combination with a biologic immunomodulator, another Janus kinase inhibitor, or a potent immunosuppressant.
      • Eligible prescriber

        • Cibinqo is prescribed by a dermatologist.
        • Cibinqo is prescribed by an allergist.
        • Cibinqo is prescribed by an immunologist.

    Continuation therapy

    Covered for reauthorization when all of the following are met.

    • Documentation shows a positive clinical response to Cibinqo therapy.
    • The patient is not receiving Cibinqo in combination with a biologic immunomodulator, another Janus kinase inhibitor, or a potent immunosuppressant.
    • Prescriber requirement

      • Cibinqo is prescribed by a dermatologist or in consultation with a dermatologist.
      • Cibinqo is prescribed by an allergist or in consultation with an allergist.
      • Cibinqo is prescribed by an immunologist or in consultation with an immunologist.

    Cibinqo should not be used in combination with other Janus kinase (JAK) inhibitors, biologic immunomodulators, or other immunosuppressants.

    Coverage requires that the patient not receive Cibinqo concurrently with a biologic immunomodulator, another JAK inhibitor, or a potent immunosuppressant. Examples include Adbry, Dupixent, Ebglyss, Nemluvio, Olumiant, Opzelura, Rinvoq, Xeljanz/XR, azathioprine, cyclosporine, and mycophenolate mofetil.

    Coding and Reference Information

    Diagnostic reference codeICD-10
    300.29Specific phobia diagnostic criteria referenced in DSM-V-TR
    Systemic Atopic-Dermatitis Treatment Trial
    Required trial duration3 months
    Supporting documentationMedical records, such as chart notes and laboratory values, must document the systemic drug-product trial.
    Claims historyPrescription claims history may supplement documentation of medication use, dose, and duration.
    Topical Therapeutic Classes
    Required number of classesFailure, contraindication, or intolerance to 2 therapeutic classes
    Qualifying class 1Medium-, high-, or very-high-potency topical corticosteroid

    Provider Requirements and Documentation

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for initial Cibinqo approval. Approval requires moderate-to-severe chronic atopic dermatitis and satisfaction of either the new-start pathway or the current-user pathway, plus all applicable safety and prescriber requirements.

    • Diagnosis of moderate-to-severe chronic atopic dermatitis.
    • Meet either the required topical and systemic-treatment pathway or the current-user pathway.
    • Do not use Cibinqo with prohibited concurrent therapies, and ensure prescribing by a dermatologist, allergist, or immunologist.
    Prior Authorization

    Reauthorization Requirements

    Reauthorization requires documented benefit and continued compliance with the policy. The patient must demonstrate a positive clinical response, must not receive Cibinqo with prohibited combination therapies, and must be prescribed by or be under consultation with a qualifying specialist.

    • Document positive clinical response to Cibinqo therapy.

    Clinical Background

    Cibinqo (abrocitinib) is a Janus kinase inhibitor indicated for adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe chronic atopic dermatitis. Coverage applies when the disease is not adequately controlled with other systemic drug products, including biologics, or when those therapies are inadvisable. Cibinqo is not recommended in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.

    Definitions

    Qualifying Needle Phobia
    DefinitionA documented needle phobia
    Required severityThe phobia must be severe enough that the patient has previously refused any injectable therapy or medical procedure.
    Diagnostic referenceDSM-V-TR 300.29 is referenced for specific-phobia diagnostic criteria.

    Initial Therapy Criteria

    Cibinqo initial authorization

    Initial authorization requires the applicable treatment-history, safety, and specialist-prescriber criteria.

    • Diagnosis: The patient has moderate-to-severe chronic atopic dermatitis.
    • Treatment-history pathway

      • New-to-therapy pathway

        • Topical therapy history: The patient has a history of failure, contraindication, or intolerance to two of the following therapeutic classes: a medium-, high-, or very-high-potency topical corticosteroid; a topical calcineurin inhibitor; or Eucrisa (crisaborole).2 classes

          Document the drug, date of trial, and/or contraindication. Eucrisa requires prior authorization.

    Continuation and Reauthorization Criteria

    Cibinqo reauthorization

    Reauthorization is approved when all criteria are met.

    • Documentation shows a positive clinical response to Cibinqo therapy.
    • The patient is not receiving Cibinqo in combination with a biologic immunomodulator, another Janus kinase inhibitor, or a potent immunosuppressant.
    • Prescriber or consultation requirement

      • Cibinqo is prescribed by or in consultation with a dermatologist.
      • Cibinqo is prescribed by or in consultation with an allergist.

    Step-Therapy Requirements

    StepRequirementQualifying therapies
    {"text":"1","status":""},{"text":"Try two topical-therapy classes with documented failure, contraindication, or intolerance.","status":""},{"text":"Medium-, high-, or very-high-potency topical corticosteroid; topical calcineurin inhibitor; or Eucrisa (crisaborole).","status":""}
    StepRequirementDocumentation
    {"text":"2","status":""},{"text":"Complete a systemic atopic-dermatitis drug-product trial for 3 months with inadequate control.","status":""},{"text":"Submit medical records documenting the trial; prescription claims history may supplement documentation of medication use, dose, and duration. The physician must attest that the patient was not adequately controlled.","status":""}
    StepAlternative requirementDocumentation
    {"text":"2","status":""},{"text":"Document that chronic systemic treatment with each listed FDA-approved atopic-dermatitis therapy is inadvisable.","status":""},{"text":"Adbry (tralokinumab-ldrm), Dupixent (dupilumab), Ebglyss (lebrikizumab-lbkz), and Nemluvio (nemolizumab-ilto); document each drug and the contraindication rationale.","status":""}

    Quantity Limits

    Quantity Limits
    MedicationCibinqo
    Supply limitSupply limits may be in place.
    Limit amountNot specified
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyCibinqo (abrocitinib) Prior Authorization for Atopic Dermatitis
    Policy CodePolicy N/A
    Change TypeMinor revision
    Effective DateOct 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of a three-month systemic atopic-dermatitis treatment trial and physician attestation of inadequate control for standard initial authorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Reference InformationProvider Requirements and DocumentationClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation and Reauthorization CriteriaStep-Therapy RequirementsQuantity Limits
    Qualifying class 2
    Topical calcineurin inhibitor
    Qualifying class 3Eucrisa (crisaborole)
  1. Confirm that Cibinqo is not being used with a biologic immunomodulator, Janus kinase inhibitor, or potent immunosuppressant.
  2. The prescription must be from or made in consultation with a dermatologist, allergist, or immunologist.
  3. Step Therapy

    Topical Therapy Step Requirement

    Patients starting Cibinqo must have a documented history of failure, contraindication, or intolerance to two qualifying topical therapeutic classes.

    • Medium-, high-, or very-high-potency topical corticosteroid (for example, mometasone furoate, fluocinolone acetonide, or fluocinonide).
    • Topical calcineurin inhibitor (pimecrolimus or tacrolimus).
    • Eucrisa (crisaborole).
    • For each topical therapy, document the drug, date of trial, and, when applicable, the contraindication or intolerance.
    Step Therapy

    Systemic Therapy Step Requirement

    The initial-authorization pathway requires a 3-month trial of a systemic drug product for atopic dermatitis unless an applicable exception is documented.

    • Examples include Adbry (tralokinumab-ldrm), Dupixent (dupilumab), Ebglyss (lebrikizumab-lbkz), and Nemluvio (nemolizumab-ilto).
    • A qualifying exception is physician attestation that treatment with all listed FDA-approved chronic atopic dermatitis therapies is inadvisable, with the drug and contraindication rationale documented.
    • A documented qualifying needle-phobia exception may also apply when the patient has previously refused injectable therapy or a medical procedure.
    Documentation Required

    Document Topical-Treatment History

    For each topical therapy used to satisfy the step requirement, submit documentation establishing the treatment history and the reason it qualifies.

    • Identify the topical drug and therapeutic class.
    • Document the date of the trial.
    • Document failure, contraindication, or intolerance, as applicable.
    • Two qualifying topical therapeutic classes are required.
    Documentation Required

    Systemic-Treatment Trial and Response

    Document the systemic-treatment trial and the patient's response before requesting initial Cibinqo authorization.

    • Submit medical records such as chart notes and laboratory values documenting a 3-month systemic-drug trial for atopic dermatitis.
    • Prescription claims history may be used with medical records to establish medication use, dose, and duration.
    • The physician must attest that the patient was not adequately controlled with the documented systemic drug product.
    Documentation Required

    Document Systemic-Therapy Exceptions

    If systemic therapy is considered inadvisable or the patient relies on the needle-phobia exception, provide a specific clinical rationale and supporting documentation.

    • For an inadvisable-treatment exception, identify each applicable therapy and document the contraindication rationale: Adbry, Dupixent, Ebglyss, and Nemluvio.
    • For the needle-phobia exception, document phobia to the degree that the patient has previously refused any injectable therapy or medical procedure.
    • Refer to DSM-V-TR 300.29 for specific-phobia diagnostic criteria when supporting the needle-phobia exception.
    Documentation Required

    Current-User Documentation

    Patients requesting approval as current Cibinqo users must demonstrate actual ongoing therapy through claims or medical records and provide the required clinical documentation.

    • Document that the patient is currently receiving Cibinqo through claims history or medical records.
    • Document the date and duration of Cibinqo therapy.
    • Patients established through a no-cost manufacturer sample or Pfizer dermatology patient access assistance must meet the initial-authorization criteria as if new to therapy; assistance alone does not establish current use.
    Documentation Required

    Positive Clinical Response Required

    For reauthorization, submit documentation showing a positive clinical response to Cibinqo therapy.

    • Include clinical documentation demonstrating meaningful benefit or improvement on therapy.
    • Positive response documentation is required at each reauthorization request.
    Denial Risk

    Prohibited Combination Therapy

    Cibinqo will not be approved or reauthorized when it is used in combination with specified immunomodulating or immunosuppressive therapies.

    • Biologic immunomodulator, including Adbry, Dupixent, Ebglyss, or Nemluvio.
    • Janus kinase inhibitor, including Olumiant, Opzelura, Rinvoq, or Xeljanz/XR.
    • Potent immunosuppressant, including azathioprine, cyclosporine, or mycophenolate mofetil.
    Prior Authorization

    Prescriber Specialty Requirement

    Initial Cibinqo therapy must be prescribed by a qualifying specialist. Reauthorization must be prescribed by or provided in consultation with one.

    • Dermatologist.
    • Allergist.
    • Immunologist.
    Documentation Required

    Insufficient Systemic-Treatment History

    When the required systemic-treatment history is not adequately documented, the request must be evaluated under the standard initial-authorization requirements rather than accepted as an established-user request.

    • Submit medical records documenting a 3-month trial of a systemic atopic-dermatitis drug product.
    • Use prescription claims history, when available, with records to establish drug use, dose, and duration.
    • Include physician attestation that the patient was not adequately controlled with the documented systemic drug product.
    Denial Risk

    Assistance Does Not Establish Current Use

    A manufacturer-supplied sample or Pfizer dermatology patient access assistance cannot, by itself, establish that a patient is a current Cibinqo user.

    • This includes a no-cost office sample or assistance such as a sample card redeemable at a pharmacy for a free supply.
    • Patients established through these sources must satisfy initial-authorization criteria as if they were new to Cibinqo therapy.
    Denial Risk

    Continuation Criteria Not Met

    Reauthorization may be denied when continuation criteria are not met, including lack of documented positive response, prohibited combination therapy, or failure to meet the specialty-prescriber requirement.

    • Document positive clinical response to Cibinqo.
    • Confirm no concurrent biologic immunomodulator, Janus kinase inhibitor, or potent immunosuppressant.
    • Ensure prescribing by or consultation with a dermatologist, allergist, or immunologist.
  4. Systemic or needle-phobia pathway

    • Systemic trial with inadequate control: Medical records document a three-month trial of a systemic drug product for atopic dermatitis, and the physician attests that the patient was not adequately controlled with the documented systemic drug product.3 months

      Claims history may supplement documentation of medication use, dose, and duration. For Connecticut, Kentucky, and Mississippi business, a 30-day trial is required.

    • Systemic treatment inadvisable: The physician attests that treatment with all of Adbry, Dupixent, Ebglyss, and Nemluvio is inadvisable and documents each contraindication rationale.
    • Qualifying needle phobia: The patient has documented needle phobia to the degree that the patient has previously refused any injectable therapy or medical procedure.

      DSM-V-TR 300.29 is referenced for specific-phobia diagnostic criteria.

  5. Established Cibinqo user: The patient is currently receiving Cibinqo as documented by claims history or medical records, with the date and duration of therapy documented, and did not establish current use through a free manufacturer-supplied sample or Pfizer dermatology patient-access assistance.

    Patients established through manufacturer assistance must meet the new-to-therapy criteria.

  6. Safety and prescriber requirements

    • The patient is not receiving Cibinqo in combination with a biologic immunomodulator, another Janus kinase inhibitor, or a potent immunosuppressant.
    • Eligible prescriber

      • Cibinqo is prescribed by a dermatologist.
      • Cibinqo is prescribed by an allergist.
      • Cibinqo is prescribed by an immunologist.
  7. Cibinqo is prescribed by or in consultation with an immunologist.